MDT

86.12

-0.15%↓

114.45

-0.44%↓

VEEV

173.4

-0.4%↓

HQY

83.98

+0.64%↑

PHR.US

8.35

-3.24%↓

MDT

86.12

-0.15%↓

114.45

-0.44%↓

VEEV

173.4

-0.4%↓

HQY

83.98

+0.64%↑

PHR.US

8.35

-3.24%↓

MDT

86.12

-0.15%↓

114.45

-0.44%↓

VEEV

173.4

-0.4%↓

HQY

83.98

+0.64%↑

PHR.US

8.35

-3.24%↓

MDT

86.12

-0.15%↓

114.45

-0.44%↓

VEEV

173.4

-0.4%↓

HQY

83.98

+0.64%↑

PHR.US

8.35

-3.24%↓

MDT

86.12

-0.15%↓

114.45

-0.44%↓

VEEV

173.4

-0.4%↓

HQY

83.98

+0.64%↑

PHR.US

8.35

-3.24%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

31.29 -1.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.01

Max

32.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-14M -81M
Pardavimai	75K 75K
Pelnas, tenkantis vienai akcijai	-1.22
Pelno marža	-108,422.667
Darbuotojai	198
EBITDA	-7.8M -81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+69.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	346M 2B
Ankstesnė atidarymo kaina	32.55
Ankstesnė uždarymo kaina	31.29

Naujienos nuotaikos

By Acuity

100%

334 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-01 22:56; UTC

Svarbiausios naujienos

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

2026-04-01 20:50; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

2026-04-01 23:55; UTC

Rinkos pokalbiai

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

2026-04-01 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

2026-04-01 23:23; UTC

Svarbiausios naujienos

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

2026-04-01 23:07; UTC

Uždarbis

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

2026-04-01 23:02; UTC

Svarbiausios naujienos

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

2026-04-01 23:00; UTC

Svarbiausios naujienos

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

2026-04-01 22:39; UTC

Uždarbis

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

2026-04-01 22:08; UTC

Rinkos pokalbiai

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

2026-04-01 22:00; UTC

Svarbiausios naujienos

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

2026-04-01 22:00; UTC

Svarbiausios naujienos

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

2026-04-01 22:00; UTC

Svarbiausios naujienos

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

2026-04-01 21:56; UTC

Įsigijimai, susijungimai, perėmimai

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

2026-04-01 21:31; UTC

Svarbiausios naujienos

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

2026-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-01 20:38; UTC

Uždarbis

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

2026-04-01 20:31; UTC

Įsigijimai, susijungimai, perėmimai

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

2026-04-01 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

2026-04-01 20:13; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Extends Tender Offer To Acquire Arcellx >GILD

2026-04-01 20:07; UTC

Rinkos pokalbiai

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

2026-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

69.96% į viršų

12 mėnesių prognozė

Vidutinis 53.91 USD 69.96%

Aukščiausias 90 USD

Žemiausias 24 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.